Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1852W HIGH $2.58
Volume
1.48 M
Value Traded
6.22 M
Short % Float
3.46%
-1.09%Week
-3.72%1 Month
+22.3%3 Month
+23.13%6 Month
-73.81%5 Year
-93.93%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
481.75 M
EPS (TTM)
-1.05
P/E Ratio
-
Ent. Value
280.12 M
Total Shares
266.16 M
Float Shares
240.53 M
Insiders
9.63%
Institutions
40.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AUTL Catalyst Timeline
Dated clinical, regulatory and corporate events for Autolus Therapeutics plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Autolus Therapeutics plc
257Total events
11Upcoming
58Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Abstractobe-cel (AUTO1)ApprovedPresentation
Abstract 2216 for CARLYSLE Phase 1 srSLE data published online ahead of ACR Convergence 2026
severe refractory systemic lupus erythematosus (srSLE)source ↗
◆Oral PresentationPresentation
William Blair 46th Annual Growth Stock Conference presentation
◆Manufacturing MilestoneCMC / Inspection
Detailed update on manufacturing life cycle plan expected in mid-2026
◆Oral Presentationobe-cel (AUTO1)ApprovedPresentation
Rapid Oral Abstract presentation at ASCO 2026 on obe-cel in B-ALL with extramedullary disease
relapsed/refractory B-cell acute lymphoblastic leukemiasource ↗
◆Abstractobe-cel (AUTO1)ApprovedPresentation
Abstract 6517 published for ASCO 2026 on obe-cel in B-ALL with extramedullary disease
relapsed/refractory B-cell acute lymphoblastic leukemiasource ↗
▲RMATobe-cel (AUTO1)ApprovedDesignation
FDA granted RMAT designation for obe-cel in pediatric r/r B-ALL
pediatric relapsed or refractory B-cell precursor ALLsource ↗
●Enrollment Updateobe-cel (AUTO1)ApprovedTrial
Phase 2 portion of CATULUS trial enrolling
pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemiasource ↗
▲Quarterly UpdateAUCATZYLApprovedCorporate
Q4 and FY2025 update: strong first year of launch of AUCATZYL in the U.S.
relapsed or refractory B-ALLsource ↗
▲FDA Filing AcceptedGazyvaFiledRegulatory Filing
FDA accepted sBLA for Gazyva/Gazyvaro for SLE
systemic lupus erythematosussource ↗
◆Trial Initiationobe-cel (AUTO1)ApprovedTrial
CATULUS trial data presented (pediatric medical need)
acute lymphoblastic leukemia (ALL)source ↗
◆Oral Presentationobe-cel (AUTO1)ApprovedPresentation
ROCCA real world experience with AUCATZYL presented
acute lymphoblastic leukemia (ALL)source ↗
▼Restructuring LayoffsCorporate
Reduction in force affecting ~13% of workforce announced in April 2026
●R&D DayPresentation
Spotlight on ALL Program virtual investor event held in April 2026
acute lymphoblastic leukemiasource ↗
▲Quarterly UpdateAUCATZYLApprovedCorporate
AUCATZYL net product revenue of $26.2 million for Q1 2026
acute lymphoblastic leukemiasource ↗
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results to be reported in March 2026
▲Enrollment Completeobe-cel (AUTO1)ApprovedTrial
CATULUS Phase 2 portion underway
pediatric r/r B-ALLsource ↗
▲Oral PresentationAUCATZYLApprovedPresentation
ROCCA real-world data presented at TANDEM meeting February 2026
acute lymphoblastic leukemiasource ↗
▲Product LaunchAUCATZYLApprovedPost-Market
UK launch of AUCATZYL via NHS
relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL)source ↗
▲Quarterly UpdateAUCATZYLApprovedCorporate
Full year 2026 AUCATZYL net product revenue guidance of $120M-$135M
acute lymphoblastic leukemiasource ↗
◆Trial Initiationobe-cel (AUTO1)ApprovedTrial
LUMINA Phase 2 trial in lupus nephritis now enrolling
lupus nephritissource ↗
◆Oral Presentationobe-cel (AUTO1)ApprovedPresentation
Updated Phase 1 CARLYSLE data in SLE at ASH
severe refractory SLEsource ↗
◆Poster Presentationobe-cel (AUTO1)ApprovedPresentation
CATULUS trial data in pediatric ALL at ASH
pediatric r/r B-ALLsource ↗
◆Poster PresentationAUTO8Presentation
Long term follow-up from AUTO8 MCARTY study at ASH
relapsed/refractory multiple myelomasource ↗
▲Oral Presentationobe-cel (AUTO1)ApprovedPresentation
Phase 1 CARLYSLE data presented at ASH 2025
severe refractory systemic lupus erythematosus (SLE)source ↗
▲Oral PresentationAUCATZYLApprovedPresentation
ROCCA consortium real-world data for AUCATZYL presented at ASH 2025
relapsed or refractory B-cell precursor acute lymphoblastic leukemiasource ↗
▲Product LaunchAUCATZYLApprovedPost-Market
Commercial launch in UK under routine commissioning
relapsed or refractory B-cell precursor acute lymphoblastic leukemiasource ↗
◆Oral Presentationobe-cel (AUTO1)ApprovedPresentation
ROCCA data comparing AUCATZYL and TECARTUS at ASH
r/r ALLsource ↗
▲Enrollment MilestoneAUCATZYLApprovedTrial
60 authorized treatment centers activated in U.S.
r/r B-ALLsource ↗
▲First Patient DosedmRNA-2808Trial
First patient dosed in Moderna's Phase 1/2 study of mRNA-2808
relapsed/refractory multiple myelomasource ↗
▲RMATobe-cel (AUTO1)ApprovedDesignation
FDA RMAT designation for obe-cel in paediatric r/r B-ALL
paediatric relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL)source ↗
▲First Patient Dosedobe-cel (AUTO1)ApprovedTrial
First patient dosed in BOBCAT Phase 1 trial in progressive MS
progressive multiple sclerosissource ↗
▲Quarterly UpdateAUCATZYLApprovedCorporate
Preliminary unaudited Q4 2025 AUCATZYL net product revenue of ~$24M
relapsed or refractory B-cell precursor acute lymphoblastic leukemiasource ↗
▲Oral Presentationobe-cel (AUTO1)ApprovedPresentation
CARLYSLE data presented at ACR Convergence 2025
severe refractory SLEsource ↗
▲EU ApprovalAUCATZYLApprovedEx-US Regulatory
EC granted conditional marketing authorization for AUCATZYL in adult patients (age 26 and older) with r/r B-ALL
relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)source ↗
▲EU ApprovalAUCATZYLApprovedEx-US Regulatory
EC marketing authorization for AUCATZYL in adult patients (age 26 and older) with r/r B-ALL
relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL)source ↗
▲Oral Presentationobe-cel (AUTO1)ApprovedPresentation
Updated long-term data from FELIX study presented at EHA 2025
relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)source ↗
Past FDA Catalysts and PDUFA Decisions
How AUTL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | PY01 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$0M
Pipeline Value
$278M
Commercial Value
Overvalued
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 84%
Micro Cap(rank 555 of 660)
Percentile Rank
Autolus Therapeutics plc faces pipeline headwinds (24/100), with 1 assets in development.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $117.4M x 2.4 = $278M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| AUCATZYL | $116M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| obe-cel (AUTO1) Cell therapyNCT07053800 | Lupus Nephritis | Phase 2 | RECRUITING | 35 | Oct 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every AUTL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| obe-cel RMAT | relapsed/refractory B-ALL and extramedullary disease | Phase 1b/2 | 2026-05-21 | overall response rate: 59%; median duration of response: 42.6 monthsRead More | Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Piccina CintiaOfficer (U.S. CCO & Country Gen Manager) | Sell | -6,713 13,287 held | $2.34 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AUTL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 0.2 % | 7.12 M | 4.45 M |
AUTL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AUTL ranks across every disease it competes in
Competitive Position is a premium feature
See how AUTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAUTL News
AUTLAutolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Autolus Therapeutics announced the online publication of an abstract for the CARLYSLE trial, which will be presented at the ACR Convergence 2026. The updated data will include safety and efficacy results from the Phase 1 study in patients with severe refractory systemic lupus erythematosus. The presentation is scheduled for November 10, 2026.
Read more →AUTLAutolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Autolus Therapeutics has received FDA RMAT designation for its therapy obe-cel, aimed at treating systemic lupus erythematosus and lupus nephritis. This designation is intended to accelerate the development of therapies for serious diseases. The next data update from the Phase 1 CARLYSLE trial is expected at the ACR Annual Meeting in late 2026, with the pivotal Phase 2 LUMINA study ongoing.
Read more →AUTL▲ +12.6%on this news
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported a strong financial performance for Q2 2026, with net product revenue from AUCATZYL reaching $45.7 million, a 119% increase year-over-year. The company has raised its FY 2026 revenue guidance to between $140 million and $150 million. Despite operational challenges, including a workforce reduction, Autolus remains optimistic about the ongoing clinical development of its therapies, particularly obe-cel, in various indications.
Read more →AUTL▲ +7.1%on this news
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
Autolus Therapeutics plc will announce its second quarter 2026 financial results on August 11, 2026. A conference call will follow to discuss these results and provide a business update. The company specializes in next-generation T cell therapies for cancer and autoimmune diseases, highlighting its commitment to innovation in biopharmaceuticals.
Read more →AUTL▲ +22.1%on this news· ran to +34% by day 3shared move
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Autolus Therapeutics reported preliminary Q2 2026 net product revenue of approximately $45 million, with a gross margin of 35%. The company increased its FY 2026 sales guidance to $140 - $150 million. Additionally, Autolus secured a $250 million credit facility with Perceptive Advisors to support its growth and development initiatives.
Read more →AUTLAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics has granted stock options and restricted stock units to 13 employees as part of its 2025 Inducement Plan. This move, compliant with Nasdaq Listing Rule 5635(c)(4), aims to incentivize new hires. The options have a ten-year term and a vesting schedule designed to encourage employee retention.
Read more →AUTLAutolus Therapeutics to Participate in Upcoming Investor Conference
Autolus Therapeutics plc will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. CEO Dr. Christian Itin is scheduled to present during a Fireside Chat on June 30, 2026. The presentation will be available via webcast and archived for 90 days. Autolus focuses on next-generation T cell therapies for cancer and autoimmune diseases.
Read more →AUTLAutolus Therapeutics Receives Prix Galien UK Award
Autolus Therapeutics has been awarded the 2026 Prix Galien UK Award for Best Biotechnology Product. This prestigious recognition, awarded by a committee of UK healthcare experts, underscores the company's commitment to developing innovative T cell therapies. Dr. Martin Pule, the company's founder, expressed pride in the award, which acknowledges the dedication of their teams in advancing treatment options for patients.
Read more →AUTLautoluannualreporta Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2025 for Autolus Therapeutics plc Introduction and Contents Autolus Therapeutics plc
Autolus Therapeutics plc has released its Annual Report for 2025, highlighting significant advancements in its T cell therapies, particularly AUCATZYL, which received FDA approval for treating adult patients with relapsed/refractory B-ALL. The company successfully launched AUCATZYL in the U.S. and U.K., though its entry into the EU market remains postponed with no sales expected in 2026. The report also conveyed positive safety data for obe-cel in pediatric patients, indicating consistent safety with low rates of serious side effects. However, concerns exist regarding the halted EU launch and market entry strategies.
Read more →AUTLAutolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics will participate in two investor conferences in June 2026. CEO Dr. Christian Itin will present at the William Blair Annual Growth Stock Conference and the Jefferies Global Healthcare Conference. Webcasts of the presentations will be available on the company's website, with replays archived for 90 days.
Read more →AUTLAutolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Autolus Therapeutics announced an abstract publication for the ASCO Annual Meeting, detailing the efficacy of obe-cel in treating patients with relapsed/refractory B-ALL and extramedullary disease. The data indicates a 59% overall response rate and a median duration of response of 42.6 months, suggesting promising potential for this treatment. The findings stem from a post-hoc analysis of the Phase Ib/II FELIX study.
Read more →AUTL▼ -7%on this news
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported strong financial results for Q1 2026, with net product revenue of $26.2 million from AUCATZYL. The company achieved a positive gross margin for its acute lymphoblastic leukemia (ALL) business and is expanding its market presence in the UK. However, it also reported a net loss of $71.6 million and announced a workforce reduction to improve operational efficiency.
Read more →AUTL▼ -7%on this news
autlex-991pr140526 Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported robust financial results for the first quarter of 2026, highlighting a net product revenue of $26.2 million for AUCATZYL, driven by successful market launches in the US and UK. The company achieved a positive gross margin for its acute lymphoblastic leukemia business, alongside ongoing clinical trials for multiple new indications. Despite these advancements, Autolus recorded a net loss of $71.6 million and announced a strategic plan to reduce its workforce by about 13% to improve operational efficiency. The company remains optimistic about its future outlook, projecting significant growth in revenue for the year.
Read more →AUTLAutolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
Autolus Therapeutics plc will announce its first quarter 2026 financial results on May 14, 2026. The company will host a conference call at 8:30 am EDT to discuss these results and provide a business update. Participants must pre-register for the call. Autolus specializes in next-generation T cell therapies for cancer and autoimmune diseases.
Read more →AUTLAutolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Autolus Therapeutics announced a strategic initiative to improve operational efficiency by reducing its workforce by approximately 13%. This restructuring is projected to save around $15 million annually starting in 2027, although it will result in one-time restructuring charges estimated at $8 million. The company continues to express confidence in its cash reserves to support operations through late 2027. CEO Dr. Christian Itin highlighted the solid performance of AUCATZYL as a catalyst for ongoing growth and profitability.
Read more →AUTLAdvancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
The biotechnology sector is shifting towards valuing scientific progress as a financial asset rather than merely a cost. This change is supported by fair-value accounting principles that allow companies to reflect clinical advancements in their financial reports. As drug candidates advance through clinical stages, their valuations increase significantly, attracting institutional investors focused on pipeline-driven value.
Read more →AUTL▲ +9.6%on this news
allinvestoreventap Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business
Autolus Therapeutics held an investor event on April 8, 2026, focusing on their product AUCATZYL for treating acute lymphoblastic leukemia (ALL). The event addressed the significant unmet medical need in treating adult patients with relapsed or refractory B-ALL. Key presentations outlined both the potential benefits and serious safety concerns related to AUCATZYL, including risks of severe infections and neurological toxicities. Future prospects for AUCATZYL depend on successful commercialization and navigating regulatory challenges.
Read more →AUTL▼ -6.2%on this news
autlex-991pr270326 Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Autolus Therapeutics reported its financial results for Q4 and the full year of 2025, revealing a net revenue of $23.3 million for the fourth quarter. The company successfully launched AUCATZYL in the UK after a positive NICE evaluation and is expanding the product's indications. Real-world data from the ROCCA consortium reaffirmed the therapy's efficacy and safety. Looking ahead, Autolus estimates 2026 revenue between $120 million to $135 million and anticipates shifting to a positive gross margin as manufacturing efficiencies improve.
Read more →About Autolus Therapeutics plc
HeadquartersTHE MEDIAWORKS, LONDON, X0, W12 7FP
Founded2018
BIOPHARMAWATCH ELITE PLUS
Trade the next AUTL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime